Table 1.
Patient and tumor characteristics of the CROSS and e-CROSS groups
| CROSS (n = 1942) | e-CROSS (n = 1359) | p Valuea | |
|---|---|---|---|
| Sex, male | 1541 (79.4) | 1044 (76.8) | 0.078 |
| Age, years [median (IQR)] | 65 (59–69) | 68 (60–76) | 0.000b |
| Missing | 0 (0.0) | 4 (0.3) | |
| Histology | 0.739 | ||
| EAC | 1544 (79.5) | 1074 (79.0) | |
| ESCC | 398 (20.5) | 285 (21.0) | |
| Tumor location | 0.007 | ||
| Mid | 277 (14.3) | 183 (13.5) | |
| Distal | 1328 (68.4) | 880 (64.8) | |
| GEJ | 333 (17.1) | 292 (21.5) | |
| Missing | 4 (0.2) | 4 (0.3) | |
| Tumor length, cm [median (IQR)] | 4.0 (3.0–6.0) | 6.0 (4.0–9.0) | 0.000b |
| Missing | 0 (0.0) | 170 (12.5) | |
| cT stage | 0.000 | ||
| T1 | 25 (1.3) | 8 (0.6) | |
| T2 | 420 (21.6) | 205 (15.1) | |
| T3 | 1455 (74.9) | 1096 (80.6) | |
| T4a | 42 (2.2) | 50 (3.6) | |
| cN stage | 0.000 | ||
| N0 | 653 (33.6) | 402 (29.6) | |
| N1 | 858 (44.2) | 562 (41.4) | |
| N2 | 337 (17.4) | 314 (23.1) | |
| N3 | 48 (2.5) | 47 (3.5) | |
| Missing | 46 (2.4) | 34 (2.5) |
Data are expressed as n (%) unless otherwise specified
Italics indicate the name of the main category
CROSS Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study, e-CROSS extended CROSS, IQR interquartile range, GEJ gastroesophageal junction, cT clinical tumor stage, cN clinical node stage, EAC esophageal adenocarcinoma, ESCC esophageal squamous cell carcinoma
aLikelihood ratio test
bMann–Whitney U test